The potential impact of vitamin D on the reduction of C-reactive protein (CRP) levels in patients infected with COVID-19

Abstract

Introduction. Vitamin D reduces illness-related inflammation and boosts the immune system. COVID-19 has aroused debate and requires substantial scientific research to produce an effective defence against distinct coronavirus strains. In COVID-19 patients, vitamin D and C-reactive protein levels were compared. Three months before the PCR test, vitamin D and C-reactive protein levels were assessed. These individuals' clinical results were also examined. Aim. Investigation of the ability of vitamin D to mitigate C-reactive protein levels in individuals with COVID-19. Materials and Methods. For the purpose of this cohort study, instances of COVID-19 were analyzed and differentiated into four distinct groups according to the levels of vitamin D that they possessed. Groups I through IV were classified according to the following parameters: concentration of 0–10 ng/ml, 10–20 ng/ml, 20–30 ng/ml, and greater than 30 ng/ml. These values served as the basis for the categorization of the samples. In order to determine the levels of vitamin D and C-reactive protein, the study used a method that had been clinically verified and was also automated. Results. The prevalence of COVID-19 was highest in the vitamin D-deficient group. Higher vitamin D levels were associated with reduced COVID-19 severity, a positive correlation with lymphocyte proportion, and a negative correlation with white blood cells and CRP. Conclusion. Vitamin D levels are inversely correlated with CRP levels and disease severity in COVID-19 patients. Vitamin D may serve as a potential biomarker for monitoring COVID-19 progression and warrants further investigation for its therapeutic implications.